Target intelligence / Profile preview

Kallikrein-1 (KLK1)

Target: KLK1
Molecular classification: Enzyme, Serine Protease, Peptidase S1 family

Overview

Kallikrein-1 (KLK1), also known as tissue kallikrein, is a serine protease enzyme that releases vasoactive peptides, particularly Lys-bradykinin, from low molecular weight kininogen. It plays roles in vasodilation, blood pressure control, and inflammation, and has been implicated in diseases like diabetic nephropathy and cancer.

Other names: KLKRKlk6hK1Tissue kallikrein

Mechanism of action

Cleaves kininogen to release Lys-bradykinin or bradykinin, activating B1R and B2R receptors.

Biological functions

VasodilationBlood Pressure ControlSmooth Muscle EffectsPain mediationInflammation mediationAngiogenesis

Disease associations

Vascular dementiaDiabetic nephropathyCancer

Biomarkers

KLK1 expression levels in cancer

Beyond the preview

Go deeper on Kallikrein-1 (KLK1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kallikrein-1 (KLK1).

Explore the full profile